Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17 ... first breakthrough into creating blood stem cells that closely resemble those in the human body.

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

In a paper published in Science Bulletin, a Chinese team of scientists reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic and phosphoproteomic analyses ...

After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...